Search hospitals > Nebraska > Omaha
Novartis Investigative Site
Claim this profileOmaha, Nebraska 68134
Global Leader in Flu
Global Leader in Influenza
Conducts research for Chronic Obstructive Pulmonary Disease
Conducts research for Obstructive Lung Diseases
Conducts research for Lung Disease
234 reported clinical trials
3 medical researchers
Summary
Novartis Investigative Site is a medical facility located in Omaha, Nebraska. This center is recognized for care of Flu, Influenza, Chronic Obstructive Pulmonary Disease, Obstructive Lung Diseases, Lung Disease and other specialties. Novartis Investigative Site is involved with conducting 234 clinical trials across 161 conditions. There are 3 research doctors associated with this hospital, such as Brandon Essink, MD, Frederick Raiser, DO, and John Hallgren.Area of expertise
1Flu
Global Leaderestrogen
ER
2Influenza
Global LeaderTop PIs
Brandon Essink, MDMeridian Clinical Research1 year of reported clinical research
Studies Viral Diseases
Studies Respiratory Syncytial Virus
3 reported clinical trials
4 drugs studied
Frederick Raiser, DOVelocity Clinical Research1 year of reported clinical research
Studies Coronavirus
2 reported clinical trials
4 drugs studied
John HallgrenNovartis Investigative Site4 years of reported clinical research
Studies Cardiovascular Disease
1 reported clinical trial
1 drug studied
Clinical Trials running at Novartis Investigative Site
Flu
Cardiovascular Disease
Low Testosterone
Respiratory Syncytial Virus Immunization
Zika Virus Infection
Zika
Zika Virus
Atherosclerosis
Type 2 Diabetes
High Blood Sugar
modRNA Vaccine
for Flu
This trial is testing a new type of flu shot that uses modified RNA to protect against four strains of the flu. It targets healthy adults aged 18 and older. The vaccine works by teaching the immune system to recognize and fight the flu virus.
Recruiting2 awards Phase 31 criteria
H2N3 Influenza Vaccine
for Flu
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, stratified by age group (born after or before 1968). Each subject will receive an influenza vaccine injection on Day 1 and Day 22. Subjects will be followed up for approximately 12 months after the second vaccine injection. The primary immunogenicity analysis is based on the Day 1, Day 8, Day 22, Day 29, and Day 43 serology data. The primary safety analysis is based on solicited local and systemic adverse events (AEs) reported within 10 days after each vaccination, unsolicited AEs reported within 3 weeks after each vaccination, and serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal from the study, and AEs of special interest (AESIs) reported throughout the study.
Recruiting1 award Phase 14 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novartis Investigative Site?
Novartis Investigative Site is a medical facility located in Omaha, Nebraska. This center is recognized for care of Flu, Influenza, Chronic Obstructive Pulmonary Disease, Obstructive Lung Diseases, Lung Disease and other specialties. Novartis Investigative Site is involved with conducting 234 clinical trials across 161 conditions. There are 3 research doctors associated with this hospital, such as Brandon Essink, MD, Frederick Raiser, DO, and John Hallgren.